Skip to main content .


HHS supports Nanomix, Inc to develop a rapid mobile diagnostic test to detect presence of current or past COVID-19 infection in patients

BARDA Response

BARDA has partnered with Nanomix, Inc. on the development of a COVID-19 rapid mobile test to diagnose COVID-19 infections with results in as little as 15 minutes. The test detects the presence of SARS-CoV-2 antigen in nasal and throat swabs. As part of the contract, a serological test will also be developed that can detect antibodies of SARS-CoV-2 in the blood, for indication of current or past COVID-19 infection.

The platform would test the patient for early evidence of infection allowing for rapid medical interventions and possibly curbing the spread of the disease. The test is being designed for near-patient locations such as hospitals, long-term care facilities, urgent care centers, and doctor’s offices, providing direct interaction with patients at the first point-of-contact, and greatly increasing the number of tests that could be run.

Nanomix’s advanced point-of-care diagnostic system, called the eLab® System has a rapid, easy to use, quantitative detection platform that performs a range of in vitro diagnostics assays. The platform consists of a hand-held reader and an integrated, self-contained, disposable, assay cartridge.

The disposable cartridge includes a biosensor and reagents to perform a highly sensitive electrochemical detection of viral particles or viral antibodies within a sample, such as a nose or throat swab. The second cartridge to be developed under the agreement will detect COVID-19 antibodies in blood samples. The assay is run by inserting the cartridge into the eLAB® Analyzer, which provides a test result within 15 minutes using an electrochemical ELISA detection method.

BARDA will contribute approximately $569,647 and Nanomix will provide the remainder of the estimated $876,000 costs. BARDA will also provide support so the company can accelerate FDA consideration of Emergency Use Authorization in the coming weeks.

This award is one component of BARDA’s Rapidly-Expanding COVID-19 Medical countermeasure portfolio, visit BARDA’s COVID-19 Portfolio to learn more.

About the Company:

This description is provided by the company and is not an indication of U.S. government endorsement of the company or its products.

Nanomix is the leader in the development of mobile point-of-care diagnostics, with a platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company designed its products to broadly impact health care delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote, or alternative settings, thus enabling faster clinical decision-making and the potential to treat in place. The company’s first assay addresses the critical need for faster sepsis diagnosis. Nanomix is developing a pipeline of other high-value tests where the rapid availability of quality diagnostic information can improve patient outcomes. More information is available at: www.nano.com.

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov